Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
Rhea-AI Summary
Ignite Proteomics (OTCQB: BACK) has announced a significant research collaboration with Inova Health to analyze tumor samples from late-stage cancer patients using their Reverse Phase Protein Array (RPPA) technology. The partnership will involve analyzing up to 600 tumor samples to generate biomarker data across various cancer-relevant drug target proteins.
The collaboration aims to help oncologists make more informed treatment decisions by providing actionable data to Inova's Molecular Tumor Board. The study will focus primarily on late-stage gastrointestinal cancers, analyzing protein targets including HER2, RET, MHC-II, EGFR, TROP2, AKT, and ERK. While financial terms weren't disclosed, this represents one of Ignite's most significant research services collaborations to date.
Positive
- First precision oncology trial using functional proteomics for pan-tumor treatment decisions
- Analysis capability of up to 600 tumor samples for comprehensive biomarker data
- Expected to contribute meaningfully to company's 2025 revenue
- One of the most significant research services collaborations for Ignite Proteomics to date
Negative
- Financial terms of the collaboration not disclosed
- Limited to primarily gastrointestinal cancers in late stages
Insights
Ignite's deal with Inova brings revenue while validating their protein analysis technology in precision oncology, advancing their diagnostic market position.
This collaboration represents a strategic advancement for Ignite Proteomics and its parent IMAC Holdings by applying their Reverse Phase Protein Array (RPPA) technology in a clinical decision-making context. The agreement to analyze up to 600 tumor samples from late-stage cancer patients positions Ignite in the growing precision oncology market, where traditional genomics approaches are being complemented by proteomics data.
The partnership with Inova Health's Molecular Tumor Board creates a real-world clinical validation of Ignite's technology, potentially establishing their RPPA platform as a valuable tool for oncologists facing difficult treatment decisions. By analyzing specific protein and phospho-protein targets like HER2, RET, and EGFR, Ignite's technology addresses a critical gap in current cancer diagnostics - directly measuring the activity of protein drug targets rather than just their genetic expression.
While financial specifics weren't disclosed, the press release indicates this is one of Ignite's "most significant research services collaborations" that will contribute meaningfully to 2025 revenue. For IMAC Holdings, this represents potential diversification of revenue streams through their Ignite subsidiary and validation in the competitive cancer diagnostics market. The focus on late-stage gastrointestinal cancers provides a defined initial application, with potential to expand to other cancer types if successful. This collaboration demonstrates commercial traction for Ignite's technology in a clinical setting beyond pure research applications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study
Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), today announced that it has entered into a research collaboration with Inova Health to apply Ignite’s Reverse Phase Protein Array (RPPA) technology to tumor samples from patients, primarily with late-stage gastrointestinal cancers. The data provided from the analysis by RPPA will be used to help oncologists select from multiple treatment options where no current guidance is available.
Under the agreement, Ignite will analyze up to 600 tumor samples to generate actionable biomarker data across a panel of cancer-relevant drug target proteins, including HER2, RET, MHC-II, EGFR, TROP2, AKT, ERK, and others. Results will be provided to Inova’s Molecular Tumor Board to assess therapy response and resistance in gastrointestinal cancers based on specific protein or phosphor-protein levels.
“This collaboration with Inova underscores the expanding applications of our RPPA technology in solid tumors,” said Faith Zaslavsky, President and CEO of Ignite Proteomics. “By partnering with Inova’s Molecular Tumor Board, we aim to accelerate precision medicine approaches for patients with gastrointestinal cancers.”
“At Inova, our mission is to bring the most advanced science into the clinic for patients who have run out of standard options” said Timothy Cannon, MD, Director of the Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova. “This collaboration gives our Molecular Tumor Board a new lens—a direct measure of the activity of the protein drug targets themselves that you cannot get from genomics analysis. This key missing information could better help guide treatment decisions in late-stage cancers, where every additional month of effective therapy matters.”
While specific financial terms were not disclosed, the agreement represents one of the most significant research services collaborations to date for Ignite Proteomics and is expected to contribute meaningfully to the Company’s 2025 revenue.
About Ignite Proteomics
Ignite Proteomics, a subsidiary of IMAC Holdings, delivers pathway‑level protein analytics to guide precision oncology. Operating a CLIA‑certified, CAP‑accredited laboratory, Ignite's clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from minute biopsy material, with many more in research stages, enabling oncologists and drug developers to match patients with the most effective targeted and immune therapies.
Forward‑Looking Statements
This press release contains forward‑looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected scope, timeline, and potential outcomes of the collaboration with Inova. Forward‑looking statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Important factors that could affect actual results include, among others, the successful completion of the research project, and the validity and reproducibility of study data. Except as required by law, IMAC Holdings undertakes no obligation to update forward‑looking statements contained herein to reflect events or circumstances after the date of this release.
Investor & Media Contact
investors@imacholdings.com | www.igniteproteomics.com
